Ben Khaled, Najib, Seidensticker, Max, Ricke, Jens, Mayerle, Julia, Oehrle, Bettina, Roessler, Daniel, Teupser, Daniel, Ehmer, Ursula, Bitzer, Michael ORCID: 0000-0002-4463-8263, Waldschmidt, Dirk, Fuchs, Martin, Reuken, Philipp A., Lange, Christian M., Wege, Henning, Kandulski, Arne, Dechene, Alexander, Venerito, Marino, Berres, Marie-Luise, Luedde, Tom ORCID: 0000-0002-6288-8821, Kubisch, Ilja, Reiter, Florian P. and De Toni, Enrico N. (2022). Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncol., 18 (12). S. 1423 - 1436. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Full text not available from this repository.

Abstract

The combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF bevacizumab is the first approved immunotherapeutic regimen for first-line therapy in patients with unresectable hepatocellular carcinoma (HCC), currently approved in more than 80 countries. The efficacy and tolerability of this regimen suggest that the use of atezolizumab bevacizumab could be extended to the treatment of patients with intermediate-stage HCC in combination with transarterial chemoembolization (TACE). The authors describe the rationale and design of the DEMAND study. This investigator-initiated, multicenter, randomized phase 2 study is the first trial to evaluate the safety and efficacy of atezolizumab bevacizumab prior to or in combination with TACE in patients with intermediate-stage HCC. The primary end point is the 24-month survival rate; secondary end points include objective response rate, progression-free survival, safety and quality of life.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Ben Khaled, NajibUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seidensticker, MaxUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ricke, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mayerle, JuliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Oehrle, BettinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roessler, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Teupser, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ehmer, UrsulaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bitzer, MichaelUNSPECIFIEDorcid.org/0000-0002-4463-8263UNSPECIFIED
Waldschmidt, DirkUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuchs, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reuken, Philipp A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lange, Christian M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wege, HenningUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kandulski, ArneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dechene, AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Venerito, MarinoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Berres, Marie-LuiseUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Luedde, TomUNSPECIFIEDorcid.org/0000-0002-6288-8821UNSPECIFIED
Kubisch, IljaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reiter, Florian P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
De Toni, Enrico N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-694619
DOI: 10.2217/fon-2021-1261
Journal or Publication Title: Future Oncol.
Volume: 18
Number: 12
Page Range: S. 1423 - 1436
Date: 2022
Publisher: FUTURE MEDICINE LTD
Place of Publication: LONDON
ISSN: 1744-8301
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ENDOTHELIAL GROWTH-FACTOR; DOUBLE-BLIND; PHASE-III; ARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; PLUS BEVACIZUMAB; SORAFENIB; CELL; MULTICENTER; COMBINATIONMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69461

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item